AscentGene is now offering more active transcription factors (including p300, p52/PSIP1, p75/LEDGF and GST-CTD), nuclear hormone receptors (including AR, ER, GR etc.) and cancer-related regulatory proteins (including c-Jun, MDM2 and
VHL). These proteins are highly demanded and available with 6His tag or GST tag that are suitable for the studies of transcription assays, protein-protein interactions and other related assays. Please contact at hge@ascentgene.com for more information or to place an order.

New Year Sale   Dec 31, 2020

2021 New Year Sale starts from Jan 1^st to Feb 15, 2021 with 15% discounted price for all products in the catalogue, including newly added protein reagents, virus-like particles for SARS-CoV2 (COVID-19) and custom services for special protein needs.

SARS–CoV -2, the novel coronavirus that  causes  the  disease  COVID -19, has  infected more than 500,000 people and caused more than 20,000 deaths…

Scientists found a potential treatment for human Glioma by an existing drug used for another disease.

Researchers from AscentGene in the United States collaborating with researchers of Nankai University in China discovered that a drug developed for non-oncology indication (AG-1031) has the potential on inhibiting the expansion of glioma (Hao et al., 2018; Wang et al, 2017).

Glioma is the most common primary and fast growing brain tumor comprising 30% of all brain and central nervous system tumors, and 80% of all malignant brain tumors. , Current therapies, including surgery, radiotherapy and chemotherapy with temozolomide (TMZ), have not resulted in major improvement  in survival outcomes of patients with glioma. Thus, novel targeted therapies are highly desired. The discovery of AG-1031 presented the evidence that an FDA approved drug showed promise as a potential treatment for glioma, but further assessments including dose tolerance, effect of combination treatment with TMZ, and direct comparison with other glioma drugs have to be conducted.

The reports, titled “AG-1031 induced autophagic cell death and apoptosis in C6 glioma cells associated with Notch-1 signaling pathway” and “AG-1031 and AG-1503 improve cognitive deficits by promoting apoptosis and inhibiting autophagy in C6 glioma model rats”, detail the preclinical studies on the effects of AG-1031 (and/or AG-1503, an analogue of AG-1031) on glioma animal models. The results provide the evidence that AG-1031 (and/or AG-1503) have significant impact in inhibiting the growth of glioma, paving the way for potential treatments in the near future.

According to National Center for Advancing Translational Sciences (NCATS), “because repurposing builds upon previous research and development efforts, new candidate therapies could be ready for clinical trials quickly, speeding their review by the Food and Drug Administration and, if approved, their integration into health care”.